欧盟EMA药品数据库(European Medicines Agency Authorisation of Medicines DataBase)
商品名称Valtropin
适用类别Human
治疗领域Turner Syndrome;Dwarfism, Pituitary
通用名/非专利名称somatropin
活性成分somatropin
产品号EMEA/H/C/000602
患者安全信息No
许可状态Withdrawn
ATC编码H01AC01
是否额外监管No
是否仿制药或hybrid药物No
是否生物类似药Yes
是否附条件批准No
是否特殊情形No
是否加速审评No
是否罕用药No
上市许可日期2006/04/24
上市许可开发者/申请人/持有人BioPartners GmbH
人用药物治疗学分组Pituitary and hypothalamic hormones and analogues
兽用药物治疗学分组
欧盟委员会决定日期2012/05/10
修订号5
治疗适应症Paediatric poulation Long-term treatment of children (2 to 11 years old) and adolescents (12 to 18 years old) with growth failure due to an inadequate secretion of normal endogenous growth hormone. Treatment of short stature in children with Turner syndrome, confirmed by chromosome analysis. Treatment of growth retardation in pre-pubertal children with chronic renal insufficiency. Adult patients Replacement therapy in adults with pronounced growth hormone deficiency of either childhood- or adult-onset aetiology. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated growth hormone deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like growth factor-1 (IGF-1) concentrations (< 2 standard deviation score (SDS)), who may be considered for one test. The cut-off point of the dynamic test should be strict.
适用物种
兽用药物ATC编码
首次发布日期2012/05/10
最后更新日期2012/08/14
产品说明书https://www.ema.europa.eu/en/documents/product-information/valtropin-epar-product-information_en.pdf
公共评估报告https://www.ema.europa.eu/en/medicines/human/EPAR/valtropin
©2006-2025 DrugFuture->European Medicines Agency Authorisation of Medicines DataBase